Hubei Biocause Pharmaceutical announcement, the company's controlling subsidiary China Best Life Insurance Co., Ltd. accumulated original insurance premium income from January 1, 2024, to October 31, 2024, was approximately RMB 31.386 billion yuan. The above original insurance premium income data has not been audited.
天茂集团：国华人寿保险2024年1-10月原保险保费收入约313.86亿元
Hubei Biocause Pharmaceutical: China Best Life Insurance's original insurance premium income for January-October 2024 was about 31.386 billion yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated